Biosimilar Red Tape Elimination Act

This bill, HR5526, directly amends Section 351(k) of the Public Health Service Act, eliminating the separate interchangeability determination process for biosimilar biological products. Specifically, it strikes the 'or Interchangeable' from the subsection heading and amends paragraph (4) to state, 'A biological product licensed under this subsection shall be deemed to be interchangeable with the reference product.' This means that once a biosimilar is licensed, it is automatically considered interchangeable with its reference biologic, allowing pharmacists to substitute it without prescriber intervention. This significantly streamlines market access for biosimilars, removing a key barrier that previously protected innovator biologics. The money trail shifts from innovator biologic companies to biosimilar manufacturers. Innovator biologic companies, such as Amgen ($AMGN), Pfizer ($PFE), Johnson & Johnson ($JNJ), Merck ($MRK), and Biogen ($BIIB), will see immediate and substantial pricing pressure and market share loss for their blockbuster biologics. Biosimilar manufacturers, including Viatris ($VTRS), Sandoz (a Novartis spin-off, but Viatris is a pure-play biosimilar company), and Teva Pharmaceutical Industries ($TEVA), will capture increased market share and revenue as their products gain automatic interchangeability. The mechanism is regulatory relief, which directly facilitates market entry and competition. Historically, the introduction of generic drugs has consistently led to significant price erosion for branded pharmaceuticals. For example, when the first generic version of Lipitor (atorvastatin) became available in November 2011, Pfizer's revenue from the drug plummeted by over 70% within a year. While biosimilars are not identical to generics, the principle of increased competition driving down prices holds. The Bipartisan Budget Act of 2018 included provisions to encourage biosimilar development, and subsequent market entries, such as Amgen's biosimilar for Humira (adalimumab) in 2023, demonstrated immediate pricing pressure on the reference product. This bill amplifies that effect by removing the interchangeability hurdle. Specific winners are biosimilar manufacturers like Viatris ($VTRS) and Teva Pharmaceutical Industries ($TEVA), which will see accelerated market penetration and increased sales volumes. Losers are innovator biologic companies, including Amgen ($AMGN), Pfizer ($PFE), Johnson & Johnson ($JNJ), Merck ($MRK), and Biogen ($BIIB), which will experience reduced market exclusivity, lower pricing power, and decreased revenue for their biologic portfolios. The bill was introduced by Rep. Pfluger (R-TX), a junior member, but the bipartisan co-sponsorship (including Mr. Landsman) indicates broader support. The referral to the Committee on Energy and Commerce is standard for health-related legislation. The next step is committee consideration. If it passes the Committee on Energy and Commerce, it will proceed to a House vote. Given the bipartisan nature of biosimilar promotion for cost savings, this bill has a clear path forward. The effective date of the changes would be upon enactment, immediately impacting the regulatory landscape for all new biosimilar applications.